Page last updated: 2024-11-11

cp 4126

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CP 4126: the elaidic acid ester of gemcitabine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9828310
CHEMBL ID3039516
CHEBI ID177710
SCHEMBL ID582034
SCHEMBL ID582036
MeSH IDM0533324

Synonyms (43)

Synonym
210829-30-4
gemcitabine elaidate
[(2r,3r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-diluoro-3-hydroxyoxolan-2-yl]methyl (e)-octadec-9-enoate
CHEBI:177710
gemcitabine elaidate (usan/inn)
D10222
co-101
cp-4126
co-1.01
gemcitabine elaidate [usan:inn]
231c73w7lg ,
4-amino-1-(2-deoxy-2,2-difluoro-5-o-((9e)-octadec-9-enoyl)-alpha-d-erythro- pentofuranosyl)pyrimidin-2(1h)-one
cp 4126
unii-231c73w7lg
2'-deoxy-2',2'-difluorocytidine 5'-(9e)-octadec-9-enoate
cytidine, 2'-deoxy-2',2'-difluoro-, 5'-(9e)-9-octadecenoate
gemcitabine elaidate [inn]
5'-o-(trans-9''-octadecenoyl)-1-.beta.-d-2'deoxy-2',2'-difluorocytidine
gemcitabine elaidate [usan]
gemcitabine elaidate [who-dd]
CHEMBL3039516
cp-4126 (lvt derivative of gemcitabine)
SCHEMBL582034
SCHEMBL582036
CS-3744
AC-35279
HY-13538
DTXSID00175308
J-520106
gemcitabine (elaidate)
AKOS030526715
DB12564
[(2r,3r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (e)-octadec-9-enoate
gemcitabine-elaidate
nsc-765775
nsc765775
Q27253699
(e)-((2r,3r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methyl octadec-9-enoate.
F85108
MS-29772
gemcitabine 5'-elaidatecp-4126
gemcitabine 5'-elaidate
hessnrgievbprb-qddpnbljsa-n

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of CP-4126, and to describe its pharmacokinetic profile."( A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.
Aamdal, S; Awada, A; Dueland, S; Evans, TR; Hagen, S; Hendlisz, A; Hernes, K; Rasch, W; Venugopal, B, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"01 dosed at 1250 mg/m(2) on Days 1, 8, and 15 of a 4-week cycle."( A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Allen, A; Bahary, N; Dragovich, T; Hosein, PJ; Laheru, D; LaValle, J; Li, D; Lowery, MA; O'Reilly, EM; Pant, S; Rolfe, L; Ryan, DP; Saif, MW; Yu, KH,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (50.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]